Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
652 ARTICLES BY Jacob Bell
- July 20, 2018 Roche bets over $1B on tech that lets patients swallow antisense drugs
- July 19, 2018 7 companies to watch during Q2 earnings
- July 19, 2018 Allergan's eye drug stacks up against Lucentis, but wider market still iffy
- July 18, 2018 AbbVie goes 3-0 in delaying Humira rivals
- July 18, 2018 Where does J&J's new drug fit in the crowded HIV market?
- July 17, 2018 J&J: Growth not dependent on Zytiga
- July 16, 2018 5 drugs to watch as biotechs report Q2
- July 13, 2018 Advaxis clinical hold lifted, but stock not so much
- July 12, 2018 New epilepsy data sets Zogenix up for showdown with GW
- July 11, 2018 Dova downgraded as high price tag threatens to slow new drug's pickup
- July 11, 2018 Otsuka drops $430M to beef up antibody drug development
- July 10, 2018 Celgene's blood drug scores again in Phase 3
- July 9, 2018 Axovant parades new preclinical therapy, much to investor delight
- June 28, 2018 DIA18: CRISPR, AI, blockchain and the future of drug development
- June 27, 2018 DIA18: How much are PRVs even worth?
- June 26, 2018 DIA18: Value-based contracts pose more questions than answers
- June 25, 2018 What the pharma industry needs to know about vaccines
- June 25, 2018 Why be a vaccine company?
- June 24, 2018 Mustang opens CAR-T manufacturing plant, with focus on lead candidates
- June 22, 2018 Boehringer invests $268M to further build out biologics
- June 21, 2018 Incyte preps Jakafi expansion into graft-versus-host disease
- June 19, 2018 3 patients add $2.5B to Sarepta's value
- June 19, 2018 How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass
- June 18, 2018 ObsEva's endometriosis win puts it back in investors' good graces
- June 14, 2018 GSK touts two-drug HIV therapy, intends to file this year